|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 112.09 USD | +2.23% |
|
+0.30% | +21.35% |
| 07-14 | Gilead Says Yeztugo Shows Broad Effectiveness, Tolerability for Diverse HIV Prevention | MT |
| 07-14 | Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for Hiv Prevention At Ias 2025 | CI |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Discovery, Development and Commercialization of Innovative Medicines | 24.69B | 27.3B | 27.28B | 27.12B | 28.75B | |||||
Total Assets | 68.41B | 67.95B | 63.17B | 62.12B | 59B | |||||
Interest Expense | -984M | -1B | -935M | -944M | -977M | |||||
Income Tax Expense | 1.58B | 2.08B | 1.25B | 1.25B | 211M | |||||
CAPEX | -650M | -579M | -728M | -585M | -523M | |||||
EBT | 1.67B | 8.28B | 5.81B | 6.86B | 690M | |||||
D&A | 1.48B | 2.05B | 2.1B | 2.69B | 2.77B | |||||
Operating Income | 4.07B | 9.92B | 7.33B | 7.6B | 1.66B | |||||
Net Income | 123M | 6.22B | 4.59B | 5.66B | 480M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 18.22B | 19.27B | 18.88B | 19.44B | 20.59B | |||||
Total Assets | 3.8B | 4.1B | 4.5B | 4.69B | 4.79B | |||||
Europe | 4.14B | 4.87B | 4.47B | 4.31B | 4.63B | |||||
Rest of World | 2.34B | 3.16B | 3.93B | 3.37B | 3.53B | |||||
Total Assets | 897M | 963M | 973M | 626M | 627M | |||||
Japan | - | - | - | - | - |
- Stock Market
- Equities
- GILD Stock
- Financials Gilead Sciences, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition